 SpringWorks Therapeutics Inc NASDAQ: SWTX entered into a clinical trial collaboration agreement with AbbVie Inc NYSE: ABBV to evaluate SpringWorks nirogacestat combination with ABBV-383 in relapsed or refractory multiple myeloma. Gamma secretase inhibition helps prevent the cleavage and shedding of BCMA from the surface of myeloma cells. 